

Safety Data Sheet

# TAMIFLU(R) Powder for Oral Suspension

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1. Product identifier

Product name TAMIFLU(R) Powder for Oral Suspension

Product code SAP-10050891

Synonyms - TAMIFLU DRY SYRUP

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

Use - pharmaceutical active substance with antiviral effect \*1

### 1.3. Details of the supplier of the safety data sheet

Company information	Enquiries: Genentech, Inc. 1 DNA Way South San Francisco USA-CA 94080 United States of America	Local representation:
	Phone 001-(650) 225-1000	
	E-Mail info.sds@roche.com	
	US Chemtrec phone: (800)-424-9300	

### 1.4. Emergency telephone number

Emergency telephone number US Chemtrec phone: (800)-424-9300

\*1 referring to: Oseltamivir phosphate



# TAMIFLU(R) Powder for Oral Suspension

## SECTION 4: First aid measures

### 4.1. Description of first aid measures

- |              |   |
|--------------|---|
| Eye contact  | - rinse immediately with tap water for 10 minutes - open eyelids forcibly<br>- consult a physician if irritation persists |
| Skin contact | - remove immediately contaminated clothes, wash affected skin with water and soap - do not use any solvents               |
| Inhalation   | - remove the casualty to fresh air and keep him/her calm<br>- in the event of symptoms get medical treatment              |

### 4.2. Most important symptoms and effects, both acute and delayed

- |      |                            |
|------|----------------------------|
| Note | - no information available |
|------|----------------------------|

### 4.3. Indication of any immediate medical attention and special treatment needed

- |                   |                         |
|-------------------|-------------------------|
| Note to physician | - treat symptomatically |
|-------------------|-------------------------|

## SECTION 5: Firefighting measures

### 5.1. Extinguishing media

- |                              |  |
|------------------------------|--|
| Suitable extinguishing media | - adapt extinguishing media to surrounding fire conditions |
| Flash point (liquid)         | not applicable   |

### 5.2. Special hazards arising from the substance or mixture

- |                  |   |
|------------------|---|
| Specific hazards | - formation of toxic and corrosive combustion gases (nitrous oxides, phosphorous oxides) possible<br>- consider dust explosion hazard |
|------------------|---|

### 5.3. Advice for firefighters

- |                             |  |
|-----------------------------|--|
| Protection of fire-fighters | - precipitate gases/vapours/mists with water spray |
|-----------------------------|--|

## SECTION 6: Accidental release measures

### 6.1. Personal precautions, protective equipment and emergency procedures

- |                      |                               |
|----------------------|-------------------------------|
| Personal precautions | - ensure adequate ventilation |
|----------------------|-------------------------------|

### 6.2. Environmental precautions

- |                          |   |
|--------------------------|---|
| Environmental protection | - do not allow to enter drains or waterways |
|--------------------------|---|

# TAMIFLU(R) Powder for Oral Suspension

## 6.3. Methods and material for containment and cleaning up

Methods for cleaning up - collect solids (avoid dust formation) and hand over to waste removal

## SECTION 7: Handling and storage

### 7.1. Precautions for safe handling

Technical measures - processing in closed systems, if possible superposed by inert gas (e.g. nitrogen) \*1  
- local exhaust ventilation necessary \*1  
- avoid dust formation; high dust explosion hazard \*1  
- low probability of ignition: ground plant, avoid effective ignition sources \*1

### 7.2. Conditions for safe storage, including any incompatibilities

Storage conditions - below 25 °C  
- protected from light  
- do not freeze \*2

Validity - see expiry date on the label  
- ≤ 10 days, < 25 °C \*2  
- ≤ 17 days, 2 to 8 °C \*2

\*1 referring to: Oseltamivir phosphate  
\*2 referring to: TAMIFLU reconstituted suspension

## SECTION 8: Exposure controls/personal protection

### 8.1. Control parameters

Threshold value (USA) air - ACGIH-TLV: 10 mg/m<sup>3</sup> (not classifiable as a human carcinogen) \*3  
- OSHA-PEL: 15 mg/m<sup>3</sup> (total dust) \*3  
- NIOSH-REL: 0.2 mg/m<sup>3</sup> \*3

Threshold value (Roche) air - IOEL (Internal Occupational Exposure Limit): 0.2 mg/m<sup>3</sup> \*1

### 8.2. Exposure controls

Respiratory protection - Respiratory protection is recommended as a precaution to minimize exposure. Effective engineering controls are considered to be the primary means to control worker exposure. Respiratory protection should not substitute for feasible engineering controls.  
- Respiratory protection is recommended for dusty operations.

Hand protection - protective gloves (eg made of neoprene, nitrile or butyl rubber)

# TAMIFLU(R) Powder for Oral Suspension

Eye protection - safety glasses

\*1 referring to: Oseltamivir phosphate

\*3 referring to: Titanium dioxide

## SECTION 9: Physical and chemical properties

### 9.1. Information on basic physical and chemical properties

Color white to light yellow

Form powder

Odor almost odourless

Partition coefficient  $\log P_{ow}$  0.36 (octanol/water) pH 7.4 \*1

pH value (20 °C) 3.0 to 5.0 (reconstituted suspension) \*2

### 9.2. Other information

Note - no information available

\*1 referring to: Oseltamivir phosphate

\*2 referring to: TAMIFLU reconstituted suspension

## SECTION 10: Stability and reactivity

### 10.1. Reactivity

Note - no information available

### 10.2. Chemical stability

Stability - stable under the conditions mentioned in chapter 7

### 10.3. Possibility of hazardous reactions

Note - no information available

### 10.4. Conditions to avoid

Note - no information available

### 10.5. Incompatible materials

Note - no information available

# TAMIFLU(R) Powder for Oral Suspension

## 10.6. Hazardous decomposition products

Note - no information available

## SECTION 11: Toxicological information

### 11.1. Information on toxicological effects

Acute toxicity	- MNLD > 2'000 mg/kg (oral, rat)	*1
Local effects	- eye: irritant (rabbit; OECD No. 405)	*1
	- not phototoxic (in vitro)	*1
Sensitization	- sensitizing (guinea pig) (OECD No. 406)	*1
Subchronic toxicity	- NOAEL 250 mg/kg/d (oral, rat; 4 weeks)	*1
Mutagenicity	- not mutagenic (various in vitro test systems)	*1
Reproductive toxicity	- does not lower parental fertility (several species)	*1
	- not teratogenic (several species)	*1
Note	- side effects: nausea, vomiting	*1
	- therapeutic dose: 2 x 75 mg/d p.o. for 5 days	*1
Potential Health Effects	- Exposure: Inhalation, Ingestion, Skin contact, Eye contact	
	- Carcinogenicity: formulation not listed by NTP, IARC or OSHA	
	- Carcinogenicity: IARC Gr3 not classifiable	*3
*1 referring to:	Oseltamivir phosphate	
*3 referring to:	Titanium dioxide	

## SECTION 12: Ecological information

### 12.1. Toxicity

Ecotoxicity	- moderately toxic for algae ( <i>Selenastrum capricornutum</i> )	
	EbC <sub>50</sub> (96 h) 59 mg/l	
	ErC <sub>50</sub> (96 h) 463 mg/l	
	NOEbC (96 h) 10 mg/l	
	NOErC (96 h) 46 mg/l	
	(OECD No. 201)	*1
- moderately toxic for planktonic crustaceans ( <i>Daphnia magna</i> )	EC <sub>50</sub> (48 h) 33 mg/l	
	(OECD No. 202)	*1
	- barely toxic for fish (carp)	
LC <sub>50</sub> (96 h) > 100 mg/l		
(OECD No. 203)	*1	

# TAMIFLU(R) Powder for Oral Suspension

- no adverse influence on substrate biodegradation (activated sludge)  
concentration (14 d) 30 mg/l (nominal concentration)  
(MITI Test II, OECD No. 302C) \*1

## 12.2. Persistence and degradability

- Ready biodegradability
- not readily biodegradable  
3 %, 28 days  
2.8 %, 14 days  
(CO<sub>2</sub> Evolution Test, Modified Sturm Test, OECD No. 301B) \*1
- Abiotic degradation
- slow degradation, photodegradation, no significant hydrolysis 204 mg/l (measured initial concentration), water; HPLC  
~ 13 %, 120 h, ~ 22 °C, under illumination  
~ 2 %, 120 h, ~ 22 °C, dark \*1

## 12.3. Bioaccumulative potential

- Note
- no information available

## 12.4. Mobility in soil

- Note
- no information available

## 12.5. Results of PBT and vPvB assessment

- Note
- no information available

## 12.6. Other adverse effects

- Note
- no information available

\*1 referring to: Oseltamivir phosphate

## SECTION 13: Disposal considerations

### 13.1. Waste treatment methods

- Waste from residues
- return to supplier or hand over to authorized disposal company
  - observe local/national regulations regarding waste disposal
  - incinerate in qualified installation with flue gas scrubbing
  - DO NOT FLUSH unused medications or POUR them down a sink or drain. If available in your area, use takeback programs run by household hazardous waste collection programs or community pharmacies to dispose of unused and expired medicines. If you don't have access to a takeback program, dispose of these medicines in the household trash by removing them from their original containers and mixing them with an undesirable substance, such as used coffee grounds or kitty litter.

# TAMIFLU(R) Powder for Oral Suspension

## SECTION 14: Transport information

Note - not classified by transport regulations, proper shipping name non-regulated

## SECTION 15: Regulatory information

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

TSCA Status - FDA Exemption - not on inventory

Reporting Requirements - The United States Environmental Protection Agency (USEPA) has not established a Reportable Quantity (RQ) for releases of this material.  
- In New Jersey, report all releases which are likely to endanger the public health, harm the environment or cause a complaint to the NJDEPE Hotline (1-609-292-5560) and to local officials.  
- State and local regulations vary and may impose additional reporting requirements.

## SECTION 16: Other information

Full text of H-Statements referred to under section 3

H317 May cause an allergic skin reaction.  
H319 Causes serious eye irritation.  
USH003 May form combustible dust concentrations in the air

Note - Please note this Safety Data Sheet for the bulk product does not apply for the finished, packaged medicinal product intended for the final user.

Edition documentation - changes from previous version in sections 2, 3, 16

The information in this safety data sheet is based on current scientific knowledge. It should not be taken as expressing or implying any warranty concerning product characteristics.